Skip to main content

Farydak Side Effects

Generic name: panobinostat

Medically reviewed by Last updated on Nov 18, 2023.

Note: This document contains side effect information about panobinostat. Some dosage forms listed on this page may not apply to the brand name Farydak.

Applies to panobinostat: oral capsule.


Oral route (Capsule)

Severe diarrhea has been reported with panobinostat. Monitor for diarrhea, institute antidiarrheal treatment, interrupt therapy, then reduce the dose or discontinue panobinostat if necessary for severe diarrhea. Severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes have occurred in patients receiving panobinostat, and electrolyte abnormalities may exacerbate arrhythmias. A baseline ECG and electrolyte panel is recommended, along with periodic monitoring during treatment as clinically indicated.

Serious side effects of Farydak

Along with its needed effects, panobinostat (the active ingredient contained in Farydak) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking panobinostat:

More common

Less common

Other side effects of Farydak

Some side effects of panobinostat may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to panobinostat: oral capsule.


Very common (10% or more): Diarrhea (68%), nausea (36%), vomiting (26%)

Common (1% to 10%): Abdominal pain, dyspepsia, gastritis, cheilitis, abdominal distension, dry mouth, flatulence, colitis, gastrointestinal pain


Very common (10% or more): T-wave abnormalities (40%), ST-segment depression (22%), arrhythmia (12%)

Common (1% to 10%): Palpitations, hypotension, hypertension, orthostatic hypotension

Uncommon (0.1% to 1%): Cardiac ischemic events[Ref]


Very common (10% or more): Thrombocytopenia (97%), lymphopenia (82%), leukopenia (81%), neutropenia (75%), anemia (62%)

Common (1% to 10%): Grade 3/4 hemorrhage


Very common (10% or more): Severe infections (31%)

Common (1% to 10%): Hepatitis B


Common (1% to 10%): Increased blood alkaline phosphatase

Frequency not reported: Hepatic dysfunction (primarily aminotransferase and total bilirubin elevations)


Very common (10% or more): Hypocalcemia (67%), hypoalbuminemia (63%), hypophosphatemia (63%), hypokalemia (52%), hyponatremia (49%), hyperphosphatemia (29%), decreased appetite (28%), hypermagnesemia (27%), hyperbilirubinemia (21%), decreased weight (12%)

Common (1% to 10%): Hyperglycemia, dehydration, fluid retention, hypomagnesemia


Common (1% to 10%): Skin lesions, rash, erythema


Common (1% to 10%): Hypothyroidism


Common (1% to 10%): Urinary incontinence, hyperuricemia


Common (1% to 10%): Joint swelling

Nervous system

Common (1% to 10%): Dizziness, headache, syncope, tremor, dysgeusia


Very common (10% or more): Fatigue (60%), peripheral edema (29%), pyrexia (26%)

Common (1% to 10%): Chills


Common (1% to 10%): Insomnia


Very common (10% or more): Increased blood creatinine (41%)

Common (1% to 10%): Renal failure, increased blood urea, decreased glomerular filtration rate


Common (1% to 10%): Cough, dyspnea, respiratory failure, rales, wheezing


1. (2015) "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.